MAPK14 and acute myeloid leukemia: We also observed a significantreduction in the ratio m/z 4964/4632 by MALDI-TOFMS in both LPS-stimulated primary monocytes and AML samples treatedwith nilotinib as well as with the third-generation TKI, ponatinib,and the p38 inhibitor losmapimod (Figure 6A,B and Figure S1I,J), while ponatinib and bosutinib were more variable.